Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Cryptos Fall As Fed Still Fretting About Inflation
-
Why Ether Will Drastically Outperform Bitcoin In 2024
-
EHealth Spikes In View Of Better-than-expected Revenue
-
Cryptos Subdued Ahead Of Earnings Updates From Wall Street’s Tech Space
-
$ETH: MicroStrategy CEO Michael Saylor Questions the Soundness of Ethereum